Omata M, Kanda T, Wei L, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10(5):702–726. https://doi.org/10.1007/s12072-016-9717-6. (Epub 2016 Apr 29 PMID: 27130427)

Article  PubMed  Google Scholar 

Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166(9):637–648. https://doi.org/10.7326/M16-2575. (Epub 2017 Mar 21 PMID: 28319996)

Article  PubMed  PubMed Central  Google Scholar 

Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–653. https://doi.org/10.1016/S1473-3099(15)70099-X. (Epub 2015 Apr 8 PMID: 25863559)

Article  CAS  PubMed  Google Scholar 

Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762–768. https://doi.org/10.1111/jvh.12312. (Epub 2014 Sep 8 PMID: 25196837)

Article  CAS  PubMed  Google Scholar 

Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224–1231. https://doi.org/10.1016/j.jhep.2016.01.029. (Epub 2016 Jan 30 PMID: 26829205)

Article  CAS  PubMed  Google Scholar 

Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64(11):1824–1833. https://doi.org/10.1136/gutjnl-2015-310421. (PMID:26449729; PMCID:PMC5993679)

Article  CAS  PubMed  Google Scholar 

Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132(7):517–524. https://doi.org/10.7326/0003-4819-132-7-200004040-00002. (PMID: 10744587)

Article  CAS  PubMed  Google Scholar 

Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol. 2020;73(3):540–548. https://doi.org/10.1016/j.jhep.2020.03.031. (Epub 2020 Mar 31 PMID: 32243960)

Article  CAS  PubMed  Google Scholar 

Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999;131(3):174–181. https://doi.org/10.7326/0003-4819-131-3-199908030-00003. (PMID: 10428733)

Article  CAS  PubMed  Google Scholar 

Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204–1212. https://doi.org/10.1016/j.jhep.2017.07.025. (Epub 2017 Aug 9 PMID: 28802876)

Article  CAS  PubMed  Google Scholar 

Carrat F, Fontaine H, Dorival C, French ANRS CO22 Hepather cohort, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet. 2019;393(10179):1453–1464. https://doi.org/10.1016/S0140-6736(18)32111-1. (Epub 2019 Feb 11 PMID: 30765123)

Article  CAS  PubMed  Google Scholar 

Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 2018;155(2):411-421.e4. https://doi.org/10.1053/j.gastro.2018.04.008. (Epub 2018 Apr 12. PMID: 29655836)

Article  CAS  PubMed  Google Scholar 

Rinaldi L, Nevola R, Franci G, et al. Risk of hepatocellular carcinoma after HCV clearance by direct-acting antivirals treatment predictive factors and role of epigenetics. Cancers (Basel). 2020;12(6):1351. https://doi.org/10.3390/cancers12061351. (PMID: 32466400)

Article  CAS  PubMed  Google Scholar 

Ioannou GN, Beste LA, Green PK, et al. increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264-1278.e4. https://doi.org/10.1053/j.gastro.2019.07.033. (Epub 2019 Jul 26 PMID: 31356807)

Article  CAS  PubMed  Google Scholar 

Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996-1005.e1. https://doi.org/10.1053/j.gastro.2017.06.012. (Epub 2017 Jun 19 PMID: 28642197)

Article  CAS  PubMed  Google Scholar 

Kanda T, Lau GKK, Wei L, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019;13(6):649–661. https://doi.org/10.1007/s12072-019-09988-7. (Epub 2019 Sep 20. PMID: 31541423; PMCID: PMC6861433)

Article  PubMed  Google Scholar 

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol 2020;73(5):1170–1218. https://doi.org/10.1016/j.jhep.2020.08.018. (Epub 2020 Sep 15. PMID: 32956768)

Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686–721. https://doi.org/10.1002/hep.31060. (PMID: 31816111)

Article  PubMed  Google Scholar 

Chen CJ, Hsu WL, Yang HI, et al. Epidemiology of virus infection and human cancer. Recent Results Cancer Res. 2014;193:11–32. https://doi.org/10.1007/978-3-642-38965-8_2. (PMID: 24008291)

Article  PubMed  Google Scholar 

Fiorino S, Bacchi-Reggiani L, de Biase D, Fornelli A, Masetti M, et al. Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: a systematic review. World J Gastroenterol. 2015;21(45):12896–12953. https://doi.org/10.3748/wjg.v21.i45.12896. (PMID:26668515; PMCID:PMC4671046)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong SW, Choi WM, Hwang HW, et al. Chronic viral hepatitis is associated with colorectal neoplasia: a systematic review and meta-analysis. Dig Dis Sci. 2021;66(11):3715–3724. https://doi.org/10.1007/s10620-020-06745-x. (Epub 2021 Jan 12 PMID: 33433792)

Article  PubMed  Google Scholar 

Allaire M, Nahon P, Layese R, ANRS CO12 CirVir Group, et al. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology. 2018;68(4):1245–1259. https://doi.org/10.1002/hep.30034. (Epub 2018 Jul 10 PMID: 29663511)

Article  PubMed  Google Scholar 

Lam JO, Hurley LB, Lai JB, Saxena V, et al. Cancer in People with and without hepatitis C virus infection: comparison of risk before and after introduction of direct-acting antivirals. Cancer Epidemiol Biomarkers Prev. 2021;30(12):2188–2196. https://doi.org/10.1158/1055-9965.EPI-21-0742. (Epub 2021 Sep 28. PMID: 34583968; PMCID: PMC8667334)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960–974. https://doi.org/10.1053/j.gastro.2008.01.034. (Epub 2008 Jan 18 PMID: 18395077)

Article  PubMed  Google Scholar 

Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47(5):586–595. https://doi.org/10.1007/s00535-012-0533-z. (Epub 2012 Feb 11 PMID: 22328022)

Article  CAS  PubMed  Google Scholar 

Bender AP, Punyko J, Allan N, et al. Bush house & the section of chronic disease and environmental epidemiology, Minnesota department of health. A standard person-years approach to estimating lifetime cancer risk. Cancer Causes Control. 1992;3:69–75 (PMID: 1536916)

Article  CAS  PubMed  Google Scholar 

Naing NN. Easy way to learn standardization: direct and indirect methods. Malays J Med Sci. 2000;7(1):10–15 (PMID: 22844209)

CAS  PubMed  PubMed Central  Google Scholar 

Matsuda A, Matsuda T, Shibata A, et al. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2014;44(4):388–396. https://doi.org/10.1093/jjco/hyu003. (Epub 2014 Feb 5. PMID: 24503029)

Article  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. https://doi.org/10.1038/bmt.2012.244. (Epub 2012 Dec 3. PMID: 23208313; PMCID: PMC3590441)

Article  CAS  PubMed  Google Scholar 

Rodger AJ, Jolley D, Thompson SC, et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30(5):1299–1301. https://doi.org/10.1002/hep.510300504. (PMID: 10534353)

Article  CAS  PubMed  Google Scholar 

CANCER INCIDENCE OF JAPAN 2017; Cancer and disease control division, Ministry of Health, Labor and Welfare, Japan. https://ganjoho.jp/reg_stat/statistics/data/dl/en.html. Accessed 9 Dec 2022

Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123(2):483–491. https://doi.org/10.1053/gast.2002.34785. (PMID: 12145802)

Article  CAS  PubMed  Google Scholar